BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37691270)

  • 1. Diagnostic performance of gadoxetic acid-enhanced abbreviated magnetic resonance imaging protocol in small hepatocellular carcinoma (≤2 cm) in high-risk patients.
    Wang JH; Qiu QS; Dong SY; Chen XS; Wang WT; Yang YT; Sun W; Rao SX
    Acta Radiol; 2023 Oct; 64(10):2687-2696. PubMed ID: 37691270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas.
    Whang S; Choi MH; Choi JI; Youn SY; Kim DH; Rha SE
    Eur Radiol; 2020 Aug; 30(8):4150-4163. PubMed ID: 32166493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.
    Besa C; Lewis S; Pandharipande PV; Chhatwal J; Kamath A; Cooper N; Knight-Greenfield A; Babb JS; Boffetta P; Padron N; Sirlin CB; Taouli B
    Abdom Radiol (NY); 2017 Jan; 42(1):179-190. PubMed ID: 27448609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.
    Vietti Violi N; Lewis S; Liao J; Hulkower M; Hernandez-Meza G; Smith K; Babb JS; Chin X; Song J; Said D; Kihira S; Sirlin CB; Reeder SB; Bashir MR; Fowler KJ; Ferket BS; Sigel K; Taouli B
    Eur Radiol; 2020 Nov; 30(11):6003-6013. PubMed ID: 32588209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance.
    Marks RM; Ryan A; Heba ER; Tang A; Wolfson TJ; Gamst AC; Sirlin CB; Bashir MR
    AJR Am J Roentgenol; 2015 Mar; 204(3):527-35. PubMed ID: 25714281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS; Kim SH; Song KD; Choi SY; Heo NH
    J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment.
    Jeon SK; Lee DH; Hur BY; Park SJ; Kim SW; Park J; Suh KS; Lee KW; Yi NJ; Han JK
    J Magn Reson Imaging; 2023 Nov; 58(5):1375-1383. PubMed ID: 36825827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology.
    Dong SY; Yang YT; Wang WT; Zhu S; Sun W; Zeng MS; Rao SX
    Acta Radiol; 2022 Jun; 63(6):734-742. PubMed ID: 33969700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma.
    Chou YC; Lao IH; Hsieh PL; Su YY; Mak CW; Sun DP; Sheu MJ; Kuo HT; Chen TJ; Ho CH; Kuo YT
    World J Gastroenterol; 2019 Jun; 25(21):2636-2649. PubMed ID: 31210715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging?
    Park SH; Kim B; Kim SY; Choi SJ; Huh J; Kim HJ; Kim KW; Lee SS
    Korean J Radiol; 2020 Mar; 21(3):280-289. PubMed ID: 32090520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of small hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Is the addition of diffusion-weighted MRI at 3.0T beneficial?
    Zhao XT; Li WX; Chai WM; Chen KM
    J Dig Dis; 2014 Mar; 15(3):137-45. PubMed ID: 24354621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
    Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
    Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.
    Joo I; Kim SY; Kang TW; Kim YK; Park BJ; Lee YJ; Choi JI; Lee CH; Park HS; Lee K; Kim H; Yu E; Kang HJ; Ha SY; Kim JY; Ahn S; Jung ES; Kim BH; Han HS; Lee JM
    Radiology; 2020 Aug; 296(2):335-345. PubMed ID: 32484414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
    Rong D; He B; Tang W; Xie S; Kuang S; Grazioli L; Hussain SM; Yang Y; Wang J
    AJR Am J Roentgenol; 2022 Apr; 218(4):687-698. PubMed ID: 34817191
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.